Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been given a consensus rating of “Moderate Buy” by the six research firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $57.40.

ESTA has been the topic of a number of analyst reports. Stephens reiterated an “overweight” rating and set a $52.00 target price on shares of Establishment Labs in a report on Thursday, March 6th. Needham & Company LLC started coverage on Establishment Labs in a report on Monday. They set a “hold” rating on the stock.

Establishment Labs Price Performance

Shares of ESTA opened at $30.94 on Monday. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. The business’s 50-day moving average is $36.44 and its two-hundred day moving average is $40.10. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $60.12. The company has a market capitalization of $892.50 million, a P/E ratio of -12.09 and a beta of 0.77.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The company had revenue of $44.51 million during the quarter, compared to analyst estimates of $44.45 million. Research analysts predict that Establishment Labs will post -2.41 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

A number of large investors have recently added to or reduced their stakes in ESTA. Toronto Dominion Bank bought a new stake in shares of Establishment Labs in the fourth quarter valued at approximately $24,879,000. Brown Advisory Inc. increased its stake in Establishment Labs by 23.1% in the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company’s stock valued at $107,729,000 after purchasing an additional 438,057 shares in the last quarter. Capital Research Global Investors lifted its holdings in shares of Establishment Labs by 29.3% in the 4th quarter. Capital Research Global Investors now owns 1,911,525 shares of the company’s stock worth $88,064,000 after purchasing an additional 433,484 shares in the last quarter. Voya Investment Management LLC raised its holdings in shares of Establishment Labs by 7,249.5% in the 4th quarter. Voya Investment Management LLC now owns 408,262 shares of the company’s stock worth $18,809,000 after acquiring an additional 402,707 shares during the last quarter. Finally, Millennium Management LLC grew its position in Establishment Labs by 96.9% during the fourth quarter. Millennium Management LLC now owns 711,691 shares of the company’s stock valued at $32,788,000 after buying an additional 350,213 shares during the period. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.